Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy

被引:34
作者
Chou, Shang-Yu [1 ]
Yen, Shao-Lun [5 ]
Huang, Chao-Cheng [2 ]
Huang, Eng-Yen [1 ,3 ,4 ,6 ]
机构
[1] Kaohsiung Chang Gung Mem Hosp, Dept Radiat Oncol, 123 Ta Pei Rd, Kaohsiung 83301, Taiwan
[2] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Dept Pathol, 123 Ta Pei Rd, Kaohsiung 83301, Taiwan
[3] Xiamen Chang Gung Hosp, Dept Radiat Oncol, 123 Xiafei Rd, Fujian, Peoples R China
[4] Chang Gung Univ, Coll Med, Sch Tradit Chinese Med, 259 Wenhua 1st Rd, Taoyuan, Taiwan
[5] China Med Univ, An Nan Hosp, Dept Pathol, 66,Sec 2,Changhe Rd, Tainan 709, Taiwan
[6] Kaohsiung Chang Gung Mem Hosp, Dept Radiat Oncol, 123 Ta Pei Rd, Kaohsiung 83301, Taiwan
关键词
Galectin-1; Glioblastoma multiforme; Adjuvant radiotherapy; Radioresistant marker; NEWLY-DIAGNOSED GLIOBLASTOMA; THERAPY-ONCOLOGY-GROUP; RADIATION-THERAPY; PHASE-II; GLIOMA; CELLS; TEMOZOLOMIDE; RAS; GROWTH; ASTROCYTOMA;
D O I
10.1186/s12885-018-4025-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Galectin-1, a radioresistance marker, was found in our previous study to be a prognostic factor for cervical cancer. The aim of current study is to determine the prognostic significance of the galectin-1 expression level in patients with glioblastoma multiforme (GBM) undergoing adjuvant radiotherapy (RT). Methods: We included 45 patients with GBM who were treated with maximal safe surgical resection or biopsy alone followed by adjuvant RT of EQD2 (equivalent dose in 2-Gy fractions) > or = 60 Gy for homogeneous treatment. Paraffin-embedded tissues acquired from the Department of Pathology were analyzed using immunohistochemical staining for galectin-1 expression. The primary endpoint was overall survival (OS). Results: Patients with weak expression had a better median survival (27.9 months) than did those with strong expression (10.7 months; p = 0.009). We compared characteristics between weak and strong galectin-1 expression, and only the expression level of galectin-3 showed a correlation. The group with weak galectin-1 expression displayed a 3-year OS of 27.3% and a 3-year cancer-specific survival (CSS) of 27.3%; these values were only 5.9% and 7.6%, respectively, in the group with strong galectin-1 expression (p = 0.009 and 0.020, respectively). Cox regression was used to confirm that the expression level of galectin-1 (weak vs. strong) is a significant factor of OS (p = 0.020) and CSS (p = 0.022). Other parameters, such as the expression level of galectin-3, Eastern Cooperative Oncology Group (ECOG) performance, gender, surgical method, age = 50 years, tumor size, or radiation field were not significant factors. Conclusion: The expression level of galectin-1 affects survival in patients with GBM treated with adjuvant RT. Future studies are required to analyze the effect of other factors, such as O(6)-methylguanine-DNA methyltransferase (MGMT)-promoter methylation status, in patients with weak and strong galectin-1 expression.
引用
收藏
页数:8
相关论文
共 51 条
[11]   RECURSIVE PARTITIONING ANALYSIS OF PROGNOSTIC FACTORS IN 3 RADIATION-THERAPY ONCOLOGY GROUP MALIGNANT GLIOMA TRIALS [J].
CURRAN, WJ ;
SCOTT, CB ;
HORTON, J ;
NELSON, JS ;
WEINSTEIN, AS ;
FISCHBACH, AJ ;
CHANG, CH ;
ROTMAN, M ;
ASBELL, SO ;
KRISCH, RE ;
NELSON, DF .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (09) :704-710
[12]   Removal of right cerebral hemisphere for certain tumors with hemiplegia - Preliminary report [J].
Dandy, WE .
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1928, 90 :823-825
[13]   Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: In vivo evaluation [J].
Danhier, Fabienne ;
Messaoudi, Khaled ;
Lemaire, Laurent ;
Benoit, Jean-Pierre ;
Lagarce, Frederic .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 481 (1-2) :154-161
[14]  
Dobes Martin, 2011, Surg Neurol Int, V2, P176, DOI 10.4103/2152-7806.90696
[15]   EGFR Phosphorylates Tumor-Derived EGFRvIll Driving STAT3/5 and Progression in Glioblastoma [J].
Fan, Qi-Wen ;
Cheng, Christine K. ;
Gustafson, W. Clay ;
Charron, Elizabeth ;
Zipper, Petra ;
Wong, Robyn A. ;
Chen, Justin ;
Lau, Jasmine ;
Knobbe-Thomsen, Christiane ;
Weller, Michael ;
Jura, Natalia ;
Reifenberger, Guido ;
Shokat, Kevan M. ;
Weiss, William A. .
CANCER CELL, 2013, 24 (04) :438-449
[16]  
Feldkamp MM, 1999, INT J CANCER, V81, P118, DOI 10.1002/(SICI)1097-0215(19990331)81:1<118::AID-IJC20>3.0.CO
[17]  
2-5
[18]   A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma [J].
Gilbert, Mark R. ;
Dignam, James J. ;
Armstrong, Terri S. ;
Wefel, Jeffrey S. ;
Blumenthal, Deborah T. ;
Vogelbaum, Michael A. ;
Colman, Howard ;
Chakravarti, Arnab ;
Pugh, Stephanie ;
Won, Minhee ;
Jeraj, Robert ;
Brown, Paul D. ;
Jaeckle, Kurt A. ;
Schiff, David ;
Stieber, Volker W. ;
Brachman, David G. ;
Werner-Wasik, Maria ;
Tremont-Lukats, Ivo W. ;
Sulman, Erik P. ;
Aldape, Kenneth D. ;
Curran, Walter J., Jr. ;
Mehta, Minesh P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (08) :699-708
[19]   MGMT gene silencing and benefit from temozolomide in glioblastoma [J].
Hegi, ME ;
Diserens, A ;
Gorlia, T ;
Hamou, M ;
de Tribolet, N ;
Weller, M ;
Kros, JM ;
Hainfellner, JA ;
Mason, W ;
Mariani, L ;
Bromberg, JEC ;
Hau, P ;
Mirimanoff, RO ;
Cairncross, JG ;
Janzer, RC ;
Stupp, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :997-1003
[20]   High linear-energy-transfer radiation can overcome radioresistance of glioma stem-like cells to low linear-energy-transfer radiation [J].
Hirota, Yuki ;
Masunaga, Shin-Ichiro ;
Kondo, Natsuko ;
Kawabata, Shinji ;
Hirakawa, Hirokazu ;
Yajima, Hirohiko ;
Fujimori, Akira ;
Ono, Koji ;
Kuroiwa, Toshihiko ;
Miyatake, Shin-Ichi .
JOURNAL OF RADIATION RESEARCH, 2014, 55 (01) :75-83